No abstract available.
Adult* ; Bronchoscopy* ; Foreign Bodies* ; Humans

No abstract available.
Pancreas*

No abstract available.
Pneumonia*

No abstract available.
Electrodes* ; Neural Conduction* ; Suction*

OBJECTIVES: Anticardiolipin antibody (ACA) and lupus anticoagulant (LA) are acquired antiphospholipid antibodies (APAs), which are regarded as important risk factors far vascular thrombosis and recurrent fetal loss. Although the clinical relevance of APAs in dialysis patients is uncertain, recent studies have suggested that APAs are involved in bioincompatibility and thrombogenic complications in hemadialysis (HD) patients. METHOD: We performed a cross sectional study of ACA and LA in 50 stable HD patients and their 68 vascular accesses (52 native arteriovenous fistulae and 16 synthetic arterovenous grafts), with the analysis of factors associated with the presence of APAs and the retrospective evaluation of vascular access occlusion (VAO). LA was assessed by platelet neutralization method whereas IgG-ACA was measured by a solid phase ELISA. Values higher than 23GPLU/ml (IgG phospholipid units) were considered to be positive for IgG-ACA and positive values for LA was more than 8 seconds in prolongation of the clotting time with human platelet lysate. Vascular access survival was assessed by Kaplan- Meier method, RESULTS: The mean age of the subject (M:F 21:29) was 46 years and the mean duration of hemodialysis was 49 months. The frequency of VAO in entire subjects was 0.45+/-0.98 episodes/patient year. The median value of IgG-ACA was 16.0 GPLU/ml with a distribution from 2.7 to 46.1GPLU/ ml. The median titer of I.A was 4.5 (3.1-45.6) seconds. Fourteen patients (28%) were found to have at least one episode of VAO. In spite of comparable clinical and biochemical data according to the presence of VAO, the titers of IgG-ACA (13.6+/-7.7 vs, 20.3+/-8.7GPLIJ/ml, P<0.05) and LA (4.5+/-2.9 vs. 11.7 +/-12.6sec, P<0.05) were significantly higher in VAO group. Six out of 50 patients(12%) had an increased titer of IgG-ACA and LA was found in 11 patients(22%). No patients were positive for ACA and LA simultaneously. There was no significant difference in sex, etiology of ESRD, diabetic status, the dosage of heparin during HD or the amount of erythropoietin administered according to the presence of APAs. We could not find any significant correlation between the titer of APAs and age, duration of dialysis, blood pressure, platelet count and biochemical parameters. In the patients with positive ACA, the frequency of VAO was 1.05+/-0.12 episodes/patient year, which was significantly higher than patients without ACA (0.33+/-0.17 episodes/ patient year, P<0.05). In the patients with the presence of LA(1.06+/-0.43 vs. 0.12+/-0.06 episodes/ patients year, P<0.01). The median vascular access survival time in IgG-ACA positive patients (32.7 months) was significantly decreased compared to 66.8 months in IgG-ACA negative group. CONCLUSION: Our data suggest that the presence of APAs (ACA and/or LA) affects the event-free vascular access survival in HD patients. Therefore the evaluation of APAs status have to be included in the diagnostic strategies for the patients with recurrent VAO. Further studies are necessary to explore the pharmacologic intervention method to decrease APAs and prevent VAO in HD patients.
Antibodies, Anticardiolipin* ; Antibodies, Antiphospholipid ; Arteriovenous Fistula ; Blood Platelets ; Blood Pressure ; Dialysis ; Enzyme-Linked Immunosorbent Assay ; Erythropoietin ; Heparin ; Humans ; Kidney Failure, Chronic ; Lupus Coagulation Inhibitor* ; Platelet Count ; Renal Dialysis* ; Retrospective Studies ; Risk Factors ; Thrombosis

No abstract available.

PURPOSE: Insulin-like growth factor(IGF-I) and IGF binding protein(IGFBP)-3 is thought to play an important role in fetal erythropoiesis. The objective of this study was to establish a relation between IGF-I, free IGF-I, IGFBP-1, and -3 with hemoglobin level in healthy term, 3-month, and 12-month old infants. METHODS: Healthy term infants(n=20)were enrolled at birth, as well as 3 months Erythropoiesis ; Growth Hormone ; Humans ; Infant* ; Insulin-Like Growth Factor Binding Protein 1 ; Insulin-Like Growth Factor Binding Protein 3 ; Insulin-Like Growth Factor I ; Parturition

No abstract available.
Fallopian Tubes* ; Female ; Mucous Membrane* ; Sterilization*

PURPOSE: Hormone-refractory prostate cancer(HRPC) is the terminal step in the natural history of prostate cancer, for which no chemotherapeutic agents have been shown to impact on the clinical outcomes. However, taxane-based therapies have recently appeared to have a significant efficacy on HRPC. The therapeutic effect of paclitaxel was evaluated against metastatic human prostate cancer PC-3 xenografted into athymic nude mice. MATERIALS AND METHODS: A total of 24 male nude mice subcutaneously transplanted with the PC3 cell line were divided in 2 groups. An experimental group was given paclitaxel intraperitoneally at a dose of 12.5mg/kg per injection per day for 4 consecutive days, from the 6th and 20th day following tumor injection. All mice were observed for 31 days, and sacrificed by CO2 gas asphyxiation at the end of the experiment. The mean tumor volume and body weight of both groups were compared using student's t-tests. A tumor volume of more than 200mm3 was regarded as dead. The survival rate was indirectly analyzed using the Kaplan-Meier method. RESULTS: The mean tumor volume of the paclitaxel treatment group was significantly reduced from the 20th day after tumor injection until the end of the experiment compared with the control group. The mean body weight of both groups was different significantly from the 17th day after tumor injection until the end of the experiment, but after removal of the tumor mass, at the 31st day after tumor injection, no significant difference was observed between the two groups. The survival rate of the paclitaxel treatment group was significantly higher than that of the control group. CONCLUSIONS: Our data has shown that paclitaxel is effective in suppressing the growth rate of a HRPC cell line in vivo and improved the survival rate. It is believe that further clinical assessment of the optimal dose and schedule of this drug are warranted.
Animals ; Appointments and Schedules ; Body Weight ; Cell Line* ; Heterografts* ; Humans ; Male ; Mice ; Mice, Nude* ; Natural History ; Paclitaxel* ; Prostate ; Prostatic Neoplasms ; Survival Rate ; Tumor Burden ; Xenograft Model Antitumor Assays

No abstract available.
Animals ; Burns* ; Lymphocyte Subsets* ; Lymphocytes* ; Mice* ; Spleen* ; Thymus Gland*